辅酶Ⅰ联合沙库巴曲缬沙坦对于慢性心力衰竭的前瞻性研究  

Clinical efficacy of coenzyme I combined with sakubatril-valsartan on chronic heart failure:a prospective study

作　　者：蒋燕芬 陶丽丽 姜鑫鑫 Jiang Yanfen;Tao Lili;Jiang Xinxin(904th Hospital,Chinese PLA Joint Logistics Support Force,Wuxi 214000,China;不详)

机构地区：[1]中国人民解放军联勤保障部队第九〇四医院,无锡214000

出　　处：《中国循证心血管医学杂志》2023年第12期1342-1345,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的探讨辅酶Ⅰ联合沙库巴曲缬沙坦用于慢性心力衰竭(CHF)的临床疗效。方法选取2021年2月至2023年2月于中国人民解放军联勤保障部队第九〇四医院就诊的CHF患者116例,随机分为联合组和对照组,每组各58例。对照组在常规治疗基础上,予以沙库巴曲缬沙坦进行联合治疗;联合组在对照组的基础上联用辅酶Ⅰ。比较两组患者的临床疗效、不良反应与治疗前后的心功能相关指标、血清炎症指标、6 min步行试验(6MWT)距离、明尼苏达心力衰竭生活质量量表(MLHFQ)评分等。结果治疗24周后联合组有效率为93.10%,高于对照组(79.31%,P<0.05)。治疗24周后两组左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)水平、MLHFQ评分与N末端脑钠肽前体(NT-proBNP)、超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、核因子-κB(NF-κB)水平均降低,且联合组低于对照组(P<0.05)。治疗24周后两组左室射血分数(LVEF)水平、6MWT距离均提高,且联合组高于对照组(P<0.05)。联合组不良反应发生率12.07%与对照组10.34%差异无统计学意义(P>0.05)。结论辅酶Ⅰ联合沙库巴曲缬沙坦治疗CHF可改善患者心功能,减轻炎症,提高活动耐量与生活质量,且用药安全。Objective To investigate the clinical efficacy of coenzyme I combined with sakubatril-valsartan on chronic heart failure(CHF).Methods CHF patients(n=116)were chosen and randomly divided into combined group and control group(each n=58)from the 904th Hospital,Chinese PLA Joint Logistics Support Force from Feb.2021 to Feb.2023.The control group was given sakubatril-valsartan on base of routine treatment,and combined group was additionally given coenzyme I.The clinical efficacy,adverse reactions,heart function related indexes,serum inflammatory indexes,distance of 6-minute walking test(6MWT),scores of Minnesota Living with Heart Failure Questionnaire(MLHFQ)were compared between 2 groups.Results After treatment for 24 weeks,the effective rate was 93.10%in combined group and 79.31%in control group(P<0.05).The levels of left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD),scores of MLHFQ,N-terminal pro-brain natriuretic peptide(NT-proBNP),high sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)and nuclear factor-κB(NF-κB)decreased in 2 groups,and were lower in combined group than those in control group(P<0.05).The levels of left ventricular ejection fraction(LVEF)and 6MWT distance were promoted in 2 groups,and were higher in combined group than those in control group(P<0.05).The incidence rates of adverse reactions were 12.07%in combined group and 10.34%in control group,and difference had no statistical significance(P>0.05).Conclusion Coenzyme I combined with sakubatril-valsartan,in treating CHF,can improve heart function,relieve inflammation,improve exercise tolerance and quality of life,and is safe in CHF patients.

关 键 词：辅酶I 沙库巴曲缬沙坦 慢性心力衰竭 心功能 炎症指标 

分 类 号：R514.6[医药卫生—内科学]